John McDermott is an executive with extensive experience in the life sciences and medical device industries, specializing in strategic leadership, product innovation, and global commercialization. With a proven track record of scaling businesses, and navigating complex regulatory environments, John excels in driving growth, building high-performing teams, and launching cutting-edge technologies that improve patient outcomes. Currently, John serves as the Chief Executive Officer of Vascular Therapies, a private biotechnology company focused on developing drug-eluting bioresorbable products for vascular surgery. The lead product, Sirogen, is an investigational drug currently targeted at improving outcomes for ESKD patients requiring a vascular access for hemodialysis. Previously, John was the Co-Founder and CEO of Restore Endosystems, where he led the development of the world’s first bifurcated stent graft for treating aortic occlusive disease. The company was acquired by Merit Medical. From 2008 to 2018, he served as CEO of Endologix, Inc., a company focused on minimally invasive therapies for the treatment of abdominal aortic aneurysms. John’s career includes senior leadership roles at C.R. Bard (prior to its acquisition by Becton Dickenson) where he built the Bard Peripheral Vascular division to become a leader in the treatment of peripheral vascular and renal diseases. Prior to Bard, John was the Chief Operating Officer at IMPRA, a private company focused primarily on vascular grafts for patients requiring hemodialysis. With expertise in financing, mergers and acquisitions, regulatory affairs, clinical trials, reimbursement and global sales and distribution, John is also passionate about mentoring future leaders and creating organizational cultures of quality and accountability. He holds an MBA in Marketing/International Business and a BS in Finance. He is also a named inventor on several patents for innovative vascular medical devices.